A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Amer M. Zeidan, Rory M. Shallis et al.|Annals of Hematology|2023Cited by 23
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseTed M. Getz, Aref Al‐Kali, Tariq Kewan et al.|Blood|2024Cited by 0
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate databaseJan Philipp Bewersdorf, Angela Consagra, Mikkael A. Sekeres et al.|Blood|2025Cited by 0